

# ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)  
CIN: L68200TG1986PLC006885



Date: 14.11.2025

To,

1. BSE Limited, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: 539287	2. National Stock Exchange of India Limited, Exchange Plaza, Bandra- Kurla Complex, Mumbai 400051 Symbol: ORTINGLOBE
--	---

**Sub: Outcome of Board Meeting held on 14.11.2025 under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Unit: Ortin Global Limited (formerly known as Ortin Laboratories Limited)**

Dear Sir/Madam,

With reference to the above-mentioned subject, this is to inform the Exchange that the Board meeting of Ortin Global Limited was held on Friday, the 14<sup>th</sup> day of November, 2025 at 4.10 p.m. at the Registered Office of the Company. The Board has considered and approved the following:

1. Un-audited financial results along with the Limited Review Report as per Regulation 33 of SEBI (LODR) Regulations, 2015, for the quarter and half-year ended 30.09.2025. **(Enclosed)**
2. Approval for incorporation of a Wholly Owned Subsidiary Company, namely, "ORTIN GLOBAL [DUBAI] FZ-LLC" in Dubai, UAE. **(Enclosed as Annexure - A)**

The meeting concluded at 6.20 p.m.

We request you to kindly take note of the same in your records.

Thanking you.

Yours sincerely,

**For Ortin Global Limited**  
**(formerly known as Ortin Laboratories Limited)**

**S. Murali Krishna Murthy**  
**Managing Director**  
**(DIN:00540632)**

Encl: a/

**Regd. Office: D. No. 1-8-305, Ground Floor, Chikkadpally, Musheerabad (Delivery),  
Hyderabad-500020, Telangana, India.**  
**Email:info@ortinlabsindia.com Website:www.ortinlabsindia.com**  
**Ph. No. +91 9052011118**

# ORTIN GLOBAL LIMITED

(Formerly Known as ORTIN LABORATORIES LIMITED)

CIN: L68200TG1986PLC006885



The details, as required under Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

## Annexure-A

Name(s) of the target entity, details in brief such as size, turnover etc.	Name: ORTIN GLOBAL [DUBAI] FZ-LLC Paid-up Share Capital: 30,000 USD (approx. 100000 AED) Turnover: Not Applicable
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	The proposed company will become wholly owned subsidiary after incorporation.
Industry to which the entity being acquired belongs;	Health care and Pharma
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The main objects of the proposed company will be similar as of parent company. The wholly owned subsidiary will help the parent company in creating a new market for its business operations.
Brief details of any governmental or regulatory approvals required for the acquisition;	NA (All valid UAE approvals will be taken)
Indicative time period for completion of the acquisition;	One year (tentatively)
Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
Cost of acquisition and/or the price at which the shares are acquired;	30,000 USD (approx. 100000 AED)
Percentage of shareholding / control acquired and / or number of shares acquired;	100% (Percentage of Shareholding)
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity	NA as the company is yet to be incorporated

**Regd. Office: D. No. 1-8-305, Ground Floor, Chikkadpally, Musheerabad (Delivery),  
Hyderabad-500020, Telangana, India.**

**Email: info@ortinlabsindia.com**

**Website: www.ortinlabsindia.com**

**Ph. No. +91 9052011118**



11	Total comprehensive income for the period (comprising Profit(Loss) and other comprehensive income for the period (9+10)	-50.25	-17.54	-47.24	-67.79	-57.54	-84.64	-804.10
12	Paid-up equity share capital (Face value of Rs. 10/- per share )	813.14	813.14	813.14	813.14	813.14	813.14	813.14
13	Other Equity						(615.39)	(530.75)
14	Earnings Per Share (EPS)							
	a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(0.62)	(0.22)	(0.58)	(0.83)	(0.71)	(1.04)	(9.89)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	(0.62)	(0.22)	(0.58)	(0.83)	(0.71)	(1.04)	(9.89)

**Notes:**

- (i) The above results have been recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14.11.2025.
- (ii) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting
- (iii) iii). The figures for the quarter ended September 30, 2025 and September 30, 2024 are balancing figures between the unaudited figures in respect of the first quarter and year
- (iv) Previous period figures have been regrouped / rearranged wherever necessary, to make them comparable.
- (v) The entire operations of the Company relate to only one segment hence segmental reporting as per Ind AS 108 is not applicable.
- (vi) The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the
- (vii) The results are also available on the website of the Company [www.ortinlabsindia.com](http://www.ortinlabsindia.com).

Place: Hyderabad  
Date: 14.11.2025

**For and on Behalf of the Board of Directors**  
**ORTIN GLOBAL LIMITED**  
**Formerly known as ORTIN LABORATORIES LIMITED**

MURALI KRISHNA  
MURTHY SANKA

Digitally signed by MURALI  
KRISHNA MURTHY SANKA  
Date: 2025.11.14 18:09:05 +05'30'

**S.MURALI KRISHNA MURTHY**  
**Managing Director**  
**DIN: 00540632**

**ORTIN GLOBAL LIMITED**  
Formerly known as ORTIN LABORATORIES LIMITED

**Statement of assets and Liabilities as at September 30th, 2025**

Rs in Lakhs

Standalone		
Particulars	As At 30th September, 2025	As At 31st March, 2025
<b>I. ASSETS</b>		
<b><u>(1) Non-Current Assets</u></b>		
(a) Property, Plant and Equipment	0.34	0.36
(b) Intangible Assets	-	-
(c) Capital Work in Progress	-	-
	<b>0.34</b>	<b>0.36</b>
(d) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iv) Others Financial Assets	43.94	36.97
(e) Deferred Tax Asset	5.29	6.53
(f) Long Term Loans and Advances	-	-
	<b>49.23</b>	<b>43.50</b>
<b><u>(2) Current Assets</u></b>		
(a) Inventories	0.96	1.98
(a) Financial Assets		
(i) Trade Receivables	22.52	26.12
(ii) Cash and Cash Equivalents	31.78	37.37
(iii) Bank balances other than (ii) above	-	-
(iv) Loans and Advances	-	-
(v) Other Financial Assets	-	-
(b) Current Tax Assets (Net)	-	-
(c) Other Current Assets	277.77	268.76
	<b>333.03</b>	<b>334.23</b>
<b>Total Assets</b>	<b>382.60</b>	<b>378.09</b>

<b>II. EQUITY AND LIABILITIES:-</b>		
<b><u>EQUITY</u></b>		
(a) Equity Share Capital	813.14	813.14
(b) Other Equity	(683.18)	(615.39)
	<b>129.96</b>	<b>197.75</b>
<b><u>LIABILITIES</u></b>		
<b><u>(1) Non-Current Liabilities</u></b>		
(a) Financial Liabilities		
(i) Borrowings	93.00	25.00
(b) Provisions	-	-
(c) Deferred Tax Liabilities	-	-
(d) Non Current Liabilities	-	-
	<b>93.00</b>	<b>25.00</b>
<b><u>(2) Current Liabilities</u></b>		
(a) Financial Liabilities		
(i) Borrowings	-	-

(ii) Trade Payables	5.44	4.23
(iii) Other Financial Liabilities	-	-
(b) Other Current Liabilities	154.20	151.11
(c) Provisions	-	-
(d) Current Tax Liabilities (Net)	-	-
	<b>159.64</b>	<b>155.34</b>
<b>Total Equity &amp; Liabilities</b>	<b>382.60</b>	<b>378.09</b>

**Place : Hyderabad**

**Date : 14.11.2025**

**For and on Behalf of the Board of Directors**

**ORTIN GLOBAL LIMITED**

**Formerly known as ORTIN LABORATORIES LIMITED**

MURALI KRISHNA  
MURTHY SANKA

Digitally signed by MURALI  
KRISHNA MURTHY SANKA  
Date: 2025.11.14 18:09:31 +05'30'

**S. MURALI KRISHNA MURTHY**

**Managing Director**

**DIN: 00540632**

**ORTIN GLOBAL LIMITED**  
Formerly known as **ORTIN LABORATORIES LIMITED**

**CASH FLOW STATEMENT FOR THE QUARTER ENDED 30.09.2025**

Rs in Lakhs		
Particulars	30.09.2025	31.03.2025
<b>Cash Flows from Operating Activities</b>		
<b>Net profit before tax</b>	<b>(66.55)</b>	<b>(83.75)</b>
Adjustments for :		
Finance cost recognised in profit & loss	0.15	0.27
Depreciation	0.01	1.17
Profit / Loss on Sale of Assets	(4.10)	-
<b>Operating profit before working capital changes</b>	<b>(70.49)</b>	<b>(82.31)</b>
Movements in Working Capital :		
(Increase)/Decrease in Trade and Other Receivables	3.60	150.53
(Increase)/Decrease in inventories	1.02	3.04
(Increase)/Decrease in Other financial assets	(6.97)	(13.60)
(Increase)/Decrease in Other assets	-	-
(Increase)/Decrease in Other Assets	(9.01)	(50.22)
Increase/(Decrease) in Trade Payables	1.21	(3.59)
Increase/(Decrease) in Other financial liabilities	-	-
Increase/(Decrease) in Other Current liabilities	3.10	(42.46)
Increase/(Decrease) in Provisions	-	(2.42)
<b>Changes in Working Capital</b>	<b>(7.05)</b>	<b>41.28</b>
<b>Cash generated from operations</b>	<b>(77.54)</b>	<b>(41.03)</b>
Direct Taxes Paid	-	-
<b>Net Cash from operating activities (A)</b>	<b>(77.54)</b>	<b>(41.03)</b>
<b>Cash flows from Investing Activities</b>		
Purchase of Fixed Assets	4.10	(0.36)
changes in investments	-	-
<b>Net Cash used in Investing Activities (B)</b>	<b>4.10</b>	<b>(0.36)</b>
<b>Cash flows from Financing Activities</b>		
proceeds from issue of equity investments of company	-	-
Repayment/(Proceeds) of/from borrowings	68.00	(155.23)
Finance cost	(0.15)	(0.27)
Increase/decrease in short term borrowings	-	-
(Increase)/Decrease in Other bank balances	-	188.33
<b>Net Cash used in Financing Activities (C)</b>	<b>67.85</b>	<b>32.83</b>
<b>Net Increase/(Decrease) in cash and cash equivalents (A+B+C)</b>	<b>(5.59)</b>	<b>(8.56)</b>
Cash and Cash equivalents at the beginning of the year	37.37	45.93
<b>Cash and Cash equivalents at the ending of the year</b>	<b>31.78</b>	<b>37.37</b>
Particulars	30.09.2025	31.03.2025
Cash and Cash Equivalents	31.78	37.37
Less:Short Term Borrowings From Banks	-	-
	<b>31.78</b>	<b>37.37</b>

Place : Hyderabad  
Date : 14.11.2025

For and on Behalf of the Board of  
**ORTIN GLOBAL LIMITED**  
Formerly known as **ORTIN LABORATORIES LIMITED**

MURALI KRISHNA  
MURTHY SANKA  
S. MURALI KRISHNA MURTHY  
Managing Director  
DIN: 00540632

Digitally signed by MURALI  
KRISHNA MURTHY SANKA  
Date: 2025.11.14 18:09:52 +05'30'



**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Limited Review Report on unaudited quarterly and year to date financial results of the Company**


**To The Board of Directors of Ortin Global Limited (Formerly known as Ortin Laboratories Limited)**

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Global Limited (Formerly known as Ortin Laboratories Limited) ("the Company") for the quarter ended on 30<sup>th</sup> September, 2025 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS



  
**B. V. RAMANA REDDY**  
M. No: 026967 Partner

Place: Hyderabad  
Date: 14.11.2025  
UDIN: 25026967BMMLXJ8436